Knight Therapeutics Inc. Stock Deutsche Boerse AG
Stocks
04K
CA4990531069
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Deutsche Boerse AG
02:40:48 2026-09-10 EDT
|
5-day change | 1st Jan Change | ||
| 6.150 EUR | 0.00% |
|
+2.50% | +65.32% |
| 09-02 | Knight Therapeutics Gets Regulatory Approval for TAVALISSE in Colombia | MT |
| 09-01 | Knight Therapeutics Announces Regulatory Approval of Tavalisse in Colombia | CI |
| Market Cap | 956M 692M 595M 561M 511M 66.13B 964M 6.68B 2.57B 33.54B 2.6B 2.54B 107B | P/E 2026 * |
70.3x | P/E 2027 * | 36.6x |
|---|---|---|---|---|---|
| Enterprise Value | 956M 692M 595M 561M 511M 66.13B 964M 6.68B 2.57B 33.54B 2.6B 2.54B 107B | EV / Sales 2026 * |
1.73x | EV / Sales 2027 * | 1.74x |
| Free-Float |
53.01% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Toronto S.E.
| GUD | Delayed | |
OTC Markets
| KHTR.F | Delayed | |
|
Deutsche Boerse AG
| 04K | Delayed | |
|
Tradegate
| 04K | Real-time | |
|
Boerse Muenchen
| 04K | Real-time | |
|
Börse Stuttgart
| 04K | Delayed |
Last Transcript : Knight Therapeutics Inc.
| 1 week | +2.50% | ||
| Current month | +5.13% | ||
| 1 month | +1.65% | ||
| 3 months | +7.89% | ||
| 6 months | +56.89% | ||
| Current year | +65.32% |
| 1 week | 6.15 |  | 6.2 |
| 1 month | 5.7 | | 6.25 |
| Current year | 3.54 | | 6.25 |
| 1 year | 3.46 | | 6.25 |
| 3 years | 2.94 | | 6.25 |
| 5 years | 2.88 | | 6.25 |
| 10 years | 2.88 | | 7.87 |
| Manager | Title | Age | Since |
|---|---|---|---|
Samira Sakhia
CEO | Chief Executive Officer | 57 | 2021-08-31 |
Arvind Utchanah
DFI | Director of Finance/CFO | - | 2020-03-29 |
Melanie Groleau
CTO | Chief Tech/Sci/R&D Officer | - | 2019-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Jonathan Goodman
CHM | Chairman | 58 | 2021-08-31 |
James Gale
CHM | Chairman | 77 | - |
Robert Lande
BRD | Director/Board Member | 63 | 2012-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | +2.50% | - | - | 704M | |
| -1.91% | -5.01% | +72.21% | +32.70% | 364B | |
| -0.79% | -4.50% | +21.22% | -20.04% | 67.05B | |
| -0.36% | -3.39% | +41.16% | +177.85% | 12.19B | |
| -1.47% | -9.61% | -12.47% | -16.97% | 7.58B | |
| -0.48% | -3.47% | -23.84% | +1.83% | 4.9B | |
| -1.38% | -3.07% | -33.97% | +13.49% | 4.45B | |
| -2.27% | -6.14% | -35.86% | -9.87% | 2.96B | |
| -0.90% | -5.19% | -9.78% | +36.29% | 2.45B | |
| -1.17% | -3.71% | -25.81% | -20.42% | 1.96B | |
| Average | -1.08% | -4.14% | -0.79% | +21.65% | 51.95B | |
| Weighted average by Cap. | -1.67% | -3.07% | +59.18% | +27.14% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 552M 400M 344M 324M 295M 38.22B 557M 3.86B 1.49B 19.38B 1.5B 1.47B 61.57B | 549M 397M 342M 322M 294M 37.99B 554M 3.84B 1.48B 19.27B 1.49B 1.46B 61.21B |
| Net income | 13.32M 9.64M 8.29M 7.82M 7.12M 921M 13.44M 93.14M 35.85M 467M 36.19M 35.4M 1.48B | 26.36M 19.08M 16.41M 15.48M 14.1M 1.82B 26.6M 184M 70.96M 925M 71.65M 70.08M 2.94B |
| Net Debt | - | - |
| Date | Price | Change |
|---|---|---|
| 26-09-10 | €6.150 | 0.00% |
| 26-09-09 | €6.150 | -0.81% |
| 26-09-08 | €6.200 | 0.00% |
| 26-09-07 | €6.200 | -0.80% |
| 26-09-04 | €6.250 | +4.17% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GUD Stock
- 04K Stock
Select your edition
All financial news and data tailored to specific country editions
